Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular

Clinical Trial Description

This is a multicenter, randomized, masked study to characterize the pharmacodynamics, safety and tolerability of emixustat in subjects with macular atrophy secondary to Stargardt disease. ;

Study Design

See also
Status	Clinical Trial	Phase
Terminated	`NCT01676766` - Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease	N/A
Enrolling by invitation	`NCT06048185` - Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Completed	`NCT03772665` - Safety and Efficacy of Emixustat in Stargardt Disease	Phase 3
Recruiting	`NCT04545736` - Oral Metformin for Treatment of ABCA4 Retinopathy	Phase 1/Phase 2
Recruiting	`NCT05674058` - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Completed	`NCT04909398` - Pupil Dynamics and Color Vision for the Detection of Eye Diseases	N/A
Completed	`NCT02255981` - Efficacy of Acupuncture in Macular Diseases	N/A
Completed	`NCT05266014` - This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease	Phase 1/Phase 2
Recruiting	`NCT02435940` - Inherited Retinal Degenerative Disease Registry
Completed	`NCT05417126` - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease	Phase 2
Terminated	`NCT02875704` - Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
Recruiting	`NCT03011541` - Stem Cell Ophthalmology Treatment Study II	N/A
Completed	`NCT02410122` - The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Enrolling by invitation	`NCT04239625` - Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)	Phase 2
Recruiting	`NCT05956626` - Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease	Phase 1/Phase 2
Recruiting	`NCT02402660` - Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease	Phase 2
Completed	`NCT01977846` - A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Completed	`NCT05904444` - The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies	N/A
Completed	`NCT02230228` - Phase 1 Safety Study of ALK-001 in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT06319872` - The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration	Phase 1

NCT number	NCT03033108
Study type	Interventional
Source	Kubota Vision Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	January 2017
Completion date	December 2017

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms